1. Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities
- Author
-
Nicole Pitts, Gordon Mansergh, Shanice Battle, Damian J. Denson, Elizabeth F. Closson, Jeremy Holman, Stewart Landers, Jeffrey H. Herbst, and Matthew J. Mimiaga
- Subjects
Adult ,Male ,Safe Sex ,0301 basic medicine ,Health Knowledge, Attitudes, Practice ,medicine.medical_specialty ,Urban Population ,Anti-HIV Agents ,Organophosphonates ,Black People ,HIV Infections ,Deoxycytidine ,Men who have sex with men ,Condoms ,Formative assessment ,03 medical and health sciences ,Pre-exposure prophylaxis ,Credibility ,Emtricitabine ,Humans ,Medicine ,Cities ,Homosexuality, Male ,Tenofovir ,Qualitative Research ,Chicago ,business.industry ,Adenine ,Public Health, Environmental and Occupational Health ,virus diseases ,Hispanic or Latino ,Focus Groups ,Patient Acceptance of Health Care ,030112 virology ,Focus group ,United States ,Black or African American ,Clinical trial ,Infectious Diseases ,Family medicine ,Female ,Pre-Exposure Prophylaxis ,business ,Serostatus ,Social psychology ,Qualitative research - Abstract
Men who have sex with men (MSM) of color are disproportionately affected by HIV in the United States. Pre-exposure prophylaxis (PrEP) using antiretroviral medications is a newer biomedical prevention modality with established efficacy for reducing the risk of acquiring HIV. We conducted formative qualitative research to explore audience reactions and receptivity to message concepts on PrEP as part of the development of prevention messages to promote PrEP awareness among black and Latino MSM in the United States. In 2013, 48 black and 42 Latino (total study sample = 90) mixed HIV serostatus MSM from Chicago, Ft. Lauderdale, and Kansas City participated in either an individual interview or focus group discussion. Men were recruited online and at community-based organizations in each city. We elicited feedback on the comprehensibility, credibility, and relevance of two draft messages on PrEP. The messages included efficacy estimates from iPrEx, a phase III clinical trial to ascertain whether the antiretroviral medication tenofovir/emtricitabine disoproxil fumarate (commercially known as Truvada
- Published
- 2016